GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cambium Bio Ltd (ASX:CMB) » Definitions » Common Stock

Cambium Bio (ASX:CMB) Common Stock : A$38.62 Mil (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Cambium Bio Common Stock?

Cambium Bio's quarterly common stock stayed the same from Dec. 2022 (A$38.62 Mil) to Jun. 2023 (A$38.62 Mil) and stayed the same from Jun. 2023 (A$38.62 Mil) to Dec. 2023 (A$38.62 Mil).

Cambium Bio's annual common stock increased from Jun. 2021 (A$38.29 Mil) to Jun. 2022 (A$38.62 Mil) but then stayed the same from Jun. 2022 (A$38.62 Mil) to Jun. 2023 (A$38.62 Mil).


Cambium Bio Common Stock Historical Data

The historical data trend for Cambium Bio's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cambium Bio Common Stock Chart

Cambium Bio Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.08 38.16 38.29 38.62 38.62

Cambium Bio Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.62 38.62 38.62 38.62 38.62

Cambium Bio Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Cambium Bio (ASX:CMB) Business Description

Traded in Other Exchanges
N/A
Address
16 Goodhope Street, Paddington, Sydney, NSW, AUS, 2021
Regeneus Ltd is a clinical-stage regenerative medicine company in Australia. It mainly develops a portfolio of cell-based therapies to address unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases. The company uses stem cell and immuno-oncology technologies to develop cell-based therapies. Its product pipeline consists of two platform technologies, Progenza and Sygenus, across three target therapeutic areas namely osteoarthritis, neuropathic pain, and skin wound healing. The company has one operating segment being the development of innovative cell-based therapies to address significant unmet medical needs in human and veterinary health.

Cambium Bio (ASX:CMB) Headlines

No Headlines